By manipulating GLP-1 activity, the aggregation of amyloid-β in AD can be regulated, and GLP-1 receptor agonists could alleviate hippocampal neurodegeneration (Batista et al., 2019). This evidence concerns the gene GLP1R and Alzheimer disease.